Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of e	entity
-----------	--------

MMJ PhytoTech Limited

ABN

91 601 236 417

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

⁺Class of ⁺securities issued or to be issued

Class H Performance Rights Class I Performance Rights Class J Performance Rights

Number of *securities issued or to be issued (if known) or maximum number which may be issued 833,333 Class H Performance Rights 833,333 Class I Performance Rights 833,334 Class J Performance Rights

Principal terms of the 3 +securities (e.g. if options, exercise price and expiry paid date: if partly +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Each Class H, I and J Performance Right, once vested entitles the holder to the issue of one fully paid ordinary share if exercised (at the election of the holder) on or before 26 February 2023. Subject to the holder remaining employed by the Company, the Performance Rights vest and become exercisable as follows:

- Class H Performance Rights: vest immediately upon the 20 day VWAP of Shares on the ASX being at or above \$0.60 (as adjusted for any consolidation or reconstruction of the Company's Capital) on or before 26 February 2022;
- Class I Performance Rights: vest immediately upon the 20 day VWAP of Shares on the ASX being at or above \$0.80 (as adjusted for any consolidation or reconstruction of the Company's capital) on or before 26 February 2022; and
- Class J Performance Rights: vest immediately upon the 20 day VWAP of Shares on the ASX being at or

+ See chapter 19 for defined terms.

above \$1.00 (as adjusted for any consolidation or reconstruction of the Company's capital) on or before 26 February 2022.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

Performance Rights – No. Each class of performance rights are unlisted class of securities. Shares issued upon the exercise of the Performance Rights, however, will rank equally with fully paid ordinary shares on issue.

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Issue price or consideration

5

Performance Rights were issued at \$0.0001 per Performance Right.

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Performance Rights were issued as non-cash, incentivebased remuneration to the recently appointed Chief Financial Officer of the Company under the Company's shareholder-approved Performance Rights Plan.

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in relation to the* +securities the subject of this Appendix 3B, and comply with section 6i

Yes

6b The date the security holder resolution under rule 7.1A was passed

29 November 2017

6c Number of *securities issued without security holder approval under rule 7.1

6d	Number of *securities issued with security holder approval under rule 7.1A	Nil	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	2,500,000 Perfe	ormance Rights
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Nil	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Nil	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	LR7.1 – 27,209 LR7.1A – 22,1	,
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	15 June 2018	
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	221,398,985	Fully paid ordinary shares

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	†Class
0.000.000	01
9,000,000	Class D Performance Rights
2,500,000	Class E Performance Rights
2,625,000	Class F Performance Rights
2,625,000	Class G Performance Rights
2,833,333	Class H Performance Rights
2,833,333	Class I Performance Rights
2,833,334	Class J Performance Rights
350,000	Class C Options (\$0.31, 6 May 2019)
2,500,000	Class D Options (\$0.40, 27 Jul 2018)
7,075,000	Class F Options (\$0.45, 8 Sep 2018)
2,537,500	Class G Options (\$0.36, 1 Mar 2019)
620,891	Class H Options (\$0.27, 31 Jan 2020)
1,000,000	Class I Options (\$0.24, 6 Jun 2019)
3,000,000	Class J Options (\$0.24, 1 Sep 2020)
1,500,000	Class K Options (\$0.35, 31 Oct 2021)

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Unchanged			

Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities	
-,	will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different	
	registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	

18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	

⁺ See chapter 19 for defined terms.

31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	⁺ Issue date	
	t 3 - Quotation of securities eed only complete this section if you are app Type of *securities (tick one)	
(a)	+Securities described in Part 1	
(b)		of the escrowed period, partly paid securities that become fully paid, restriction ends, securities issued on expiry or conversion of convertible
	ies that have ticked box 34(a)	
	itional securities forming a new o indicate you are providing the information	
35	1 1	ecurities, the names of the 20 largest holders of the e number and percentage of additional *securities
36	1 1	securities, a distribution schedule of the additional mber of holders in the categories
37	A copy of any trust deed for the	ne additional ⁺ securities

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end		
	of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	⁺ Class
42	Number and +class of all +securities quoted on ASX		
	(including the +securities in clause		
	38)		

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 †securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 15 June 2018

Company secretary

Print name: Erlyn Dale

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue		207,332,100
Add the following:		
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an	9/06/2017	1,600,000
exception in rule 7.2	11/09/2017	1,000,000
Number of fully paid ⁺ ordinary securities issued in that 12 month period with	15/11/2017	1,598,750
shareholder approval	12/12/2017	1,056,250
Number of partly paid +ordinary securities that became fully paid in that	29/12/2017	500,000
12 month period	12/01/2018	2,036,885
Note: • Include only ordinary securities here –	1/02/2018	1,150,000
other classes of equity securities cannot be added	2/03/2018	4,625,000
 Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of 	12/04/2018	500,000
securities on different dates as separate line items		
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period		-
"A"		221,398,985

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	33,209,848
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	
• Under an exception in rule 7.2	2/03/2018 6,000,000
• Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	6,000,000
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	33,209,848
Note: number must be same as shown in Step 2	
Subtract "C"	6,000,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	27,209,848
	[Note: this is the remaining placement capacity under rule 7.1]

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	221,398,985	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	27,209,848	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	-	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	27,209,848	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"	27,209,848	
	Note: this is the remaining placement capacity under rule 7.1A	